ESMO 2026 Debrief: A 12-Week Checkpoint Dosing Trial Stopped Early & Ivonescimab Beats Imfinzi on Survival in Biliary Cancer

The Pharma Closeout's ESMO 2026 Debrief brings you the readouts from the European Society for Medical Oncology congress in Madrid that matter, what they change, and what to watch next, with one thread running through them: how much checkpoint therapy is enough. MOIO, a French trial that spaced checkpoint-inhibitor doses to every 12 weeks in patients already responding, was stopped early on its monitoring committee's recommendation. Around bladder surgery, Merck's KEYNOTE-866 and Bristol Myers Squibb's ENERGIZE both missed event-free survival in cisplatin-eligible patients, while VOLGA won in patients ineligible for or declining cisplatin, and final PEARLS survival for adjuvant Keytruda in lung cancer missed significance. Then mismatch repair-deficient tumors, with a correction on GSK's AZUR-1 numbers; Akeso and Summit's ivonescimab beating AstraZeneca's Imfinzi on survival in biliary tract cancer at an interim analysis; Tagrisso plus Orpathys in two lines of lung cancer; Amgen's Imdelltra and a rival DLL3 drug in small-cell lung cancer; six-year NATALEE survival for Novartis's Kisqali; androgen-receptor drugs moving earlier in prostate cancer; and cancer vaccines, led by Merck and Moderna's intismeran. Plus what to watch: INTerpath-001's full results, slated for The New England Journal of Medicine on November 11, and the November 14 FDA goal date for ivonescimab in EGFR-mutated lung cancer.0:00 Cold open and introduction1:03 Story of the Congress: how much checkpoint is enough (MOIO, KEYNOTE-866, ENERGIZE, VOLGA, PEARLS)5:45 Mismatch repair-deficient tumors: KEYNOTE-C93, TroFuse-005, the AZUR-1 correction and CheckMate 8HW9:19 Biliary tract cancer: ivonescimab beats Imfinzi in HARMONi-GI110:43 Lung cancer: SAFFRON, SANOVO, sigvotatug vedotin and PERSEE13:18 Small-cell lung cancer: DeLLphi-305, ASTRIDE and IDE84914:37 Breast cancer: NATALEE at six years and postMONARCH15:53 Prostate cancer: PROTEUS, DASL-HiCaP and J&J's RIPTAC17:50 Cancer vaccines: intismeran, ELI-002 7P and DOVACC19:08 What to watch: INTerpath-001 in NEJM and the ivonescimab FDA decisionAlex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.